ERBB2 and breast cancer: This was confirmed by Farzad et al.’s study [57], which displayed another peptide, the P435 HER2-derived peptide, conjugated to liposomes capable of inducing CTL responses, therefore improving prognosis in the TUBO murine breast cancer model.